Machine Learning Can Predict Best Responders to GLP-1s (GI & Endoscopy News)

A recent study highlights the use of artificial intelligence (AI) to predict patient responses to glucagon-like peptide-1 receptor agonists (GLP-1s), such as Ozempic, for treating obesity. AI algorithms analyzed electronic health records and identified factors that help determine which patients are most likely to benefit from GLP-1 treatments. The AI-driven approach could enhance personalized treatment plans, improving efficacy and reducing the trial-and-error process in obesity management.